Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

Table 6 Utility Values for Health States and Disutility Multipliers for Treatment-emergent Adverse Events

Parameter	Value			Data Source
Health States	Full Adherence	Partial Adherence	Non-Adherence
While Stable	0.88	0.75	0.75	Lenert et al., 2004 [76];
Outpatient Relapse	0.74	0.65	0.65	Expert opinion
Inpatient Psychiatric Relapse	0.53	0.53	0.42
Treatment-Emergent Adverse Events
EPS	0.888			Lenert et al., 2004 [76]
Clinically Significant Weight Gain	0.959
Diabetes	0.888			Assumption: diabetes, hyperlipidemia, and Metabolic syndrome;
Hyperlipidemia	0.888			utilities equal EPS utility in Lenert et al., 2004 [76]

ISSN: 1478-7547